We are live on ! Find out more
NLVP

New Leaf Venture Partners Portfolio holdings

AUM $43M
1-Year Est. Return 25.55%
This Fund
S&P 500
This Quarter Est. Return
-0.32%
1 Year Est. Return
-25.55%
3 Year Est. Return
+17.13%
5 Year Est. Return
+114.46%
10 Year Est. Return
+1,011.57%
AUM
$147M
AUM Growth
-$58.2M
Cap. Flow
-$51.6M
Cap. Flow %
-35.04%
Top 10 Hldgs %
96.04%
Holding
15
New
2
Increased
5
Reduced
4
Closed
2
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
ARAV
1
DELISTED
Aravive, Inc. Common Stock
ARAV
$37.5M 25.43%
339,871
-42,874
-11% -$5.03M
RLYP
2
DELISTED
RELYPSA INC COM
RLYP
$29.6M 20.08%
819,833
-819,832
-50% -$29.6M
OXFD
3
DELISTED
Oxford Immunotec Global PLC Ordinary Shares
OXFD
$19.4M 13.17%
1,377,497
ALDR
4
DELISTED
Alder Biopharmaceuticals
ALDR
$18.3M 12.41%
633,293
+409,740
+183% +$11.2M
CMRX
5
DELISTED
Chimerix, Inc.
CMRX
$9.48M 6.44%
251,608
-816,692
-76% -$32.4M
DVAX
6
DELISTED
Dynavax Technologies
DVAX
$9.13M 6.2%
406,993
+294,293
+261% +$5.64M
CALA
7
DELISTED
Calithera Biosciences, Inc
CALA
$5.22M 3.55%
27,802
-3,437
-11% -$1.22M
MRNS
8
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$4.71M 3.2%
131,063
+26,216
+25% +$1.15M
ACAD icon
9
Acadia Pharmaceuticals
ACAD
$5.03B
$4.34M 2.94%
133,061
+64,300
+94% +$2.21M
KPTI icon
10
Karyopharm Therapeutics
KPTI
$48M
$3.88M 2.63%
8,446
GEVA
11
DELISTED
SYNAGEVA BIOPHARMA CORP COM STK (DE)
GEVA
$2.38M 1.61%
+24,379
New +$2.58M
SAGE
12
DELISTED
Sage Therapeutics
SAGE
$2.2M 1.49%
43,770
+8,400
+24% +$361K
AKAO
13
DELISTED
Achaogen Inc
AKAO
$1.26M 0.85%
+128,728
New +$1.45M
LITS
14
Lite Strategy Inc
LITS
$30.9M
-80,070
Closed -$6.84M
ALIM
15
DELISTED
Alimera Sciences
ALIM
-13,979
Closed -$1.16M

Similar funds

New Leaf Venture Partners's Q1 2015 Portfolio in Review

As of Q1 2015, New Leaf Venture Partners held 15 positions worth $147M, down 28% from $206M the previous quarter. Its ten largest holdings account for 96% of the portfolio.

New Leaf Venture Partners withdrew a net $51.6M in Q1 2015, closing 2 positions and reducing 4 holdings. Its most notable exit was Lite Strategy Inc, an estimated $6.84M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 71% of assets, up from 67% a quarter earlier.

Against the trend, New Leaf Venture Partners opened a new position in SYNAGEVA BIOPHARMA CORP COM STK (DE) worth $2.38M.

  • New Leaf Venture Partners's largest Q1 2015 buy was SYNAGEVA BIOPHARMA CORP COM STK (DE): 24,379 shares worth $2.38M.
  • New Leaf Venture Partners added most to Alder Biopharmaceuticals in Q1 2015, an estimated $11.2M increase.
  • New Leaf Venture Partners's biggest Q1 2015 reduction was Chimerix, Inc., cutting an estimated $32.4M.
  • New Leaf Venture Partners fully exited Lite Strategy Inc in Q1 2015, selling an estimated $6.84M.
  • New Leaf Venture Partners's ten largest holdings make up 96% of its $147M portfolio in Q1 2015.
  • New Leaf Venture Partners opened 2 new positions and closed 2 in Q1 2015.
  • New Leaf Venture Partners's portfolio value fell 28% quarter-over-quarter to $147M.

Based on New Leaf Venture Partners's 13F filing for Q1 2015, filed 15 May 2015.